ACUTE TELOGEN EFFLUVIUM FOLLOWING SARS-COV-2 INFECTION: A RARE PEDIATRIC CASE
Keywords:
Key words: Acute telogen effluvium, Hair loss, COVID-19, SARS-CoV-2Abstract
Telogen effluvium is a temporary, non-scarring form of diffuse hair loss, characterized by a shortened anagen phase and increased telogen club hair shedding. It can appear three months after a stressful event and may last up to six months. Various factors, including the SARS-CoV-2 virus seen during the COVID-19 pandemic, can contribute to the onset of telogen effluvium. The exact pathophysiological mechanism of hair loss caused by the virus remains unclear and continues to be under investigation. Telogen effluvium following COVID-19 has been frequently described in adults; however, there are few published cases in children. We present a rare case of post-COVID-19 telogen effluvium in a 6-year-old girl, one month after infection. The COVID-19 infection presented with mild fever, fatigue, sore throat, and upper respiratory symptoms, treated only with symptomatic therapy. Other causes of hair loss were ruled out. The dermatological evaluation showed diffuse hair loss on the scalp, more noticeable in the frontoparietal region, with no scarring, accompanied by a positive hair pull test. The diagnosis was made by the dermatologist based on the detailed anamnesis, complete laboratory workup with differential blood count, dermatological assessment, and a positive hair pull test. No medication was prescribed, and after 8 months, the condition improved on its own. This case highlights that post-COVID-19 telogen effluvium is rare in the pediatric population, emphasizing its psychological impact and the importance of reassuring the patient that it is a reversible, self-limiting condition.
References
Seyfi S, Alijanpour R, Aryanian Z, Ezoji K, Mahmoudi M. Prevalence of telogen effluvium hair loss in COVID 19 patients and its relationship with disease severity. J Med Life. 2022;15(5):631–634. doi:10.25122/jml-2021-0380
Hughes EC, Syed HA, Saleh D. Telogen Effluvium. [Updated 2024 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
Moreno Arrones OM, Lobato Berezo A, Gomez Zubiaur A, Arias Santiago S, Saceda Corralo D, Bernardez Guerra C, et al. SARS CoV 2 induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol. 2021;35(3):181–183. doi:10.1111/jdv.17045
Tešanović Perković D, Vukojević M, Bukvić Mokos Z. Post COVID Telogen Effluvium. Acta Dermatovenerol Croat. 2022;30(4):220–226. doi:10.30933/AD.30.4.3
Rossi A, Magri F, Sernicola A, Michelini S, Caro G, Muscianese M, et al. Telogen Effluvium after SARS CoV 2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms. Skin Appendage Disord. 2021;7(5):1–5. doi:10.1159/000517223
Starace M, Iorizzo M, Sechi A, Alessandrini AM, Carpanese M, Bruni F, et al. Trichodynia and telogen effluvium in COVID 19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021;5:11–18. doi:10.1016/j.jdin.2021.07.006
Bukhari AE, AlDosari DA, AlDosari MA, Muqrin RF, Moazin OM, Almutlq MM, et al. COVID 19 induced hair shedding and related risk factors: A Saudi perspective. J Family Med Prim Care. 2023;12:3304–3311. doi:10.4103/jfmpc.jfmpc_129_23
Hayran Y, Yorulmaz A, Gur G, Aktas A. Different hair loss patterns in two pediatric patients with COVID 19 associated multisystem inflammatory syndrome in children. Dermatol Ther. 2021;34(4):e15053. doi:10.1111/dth.15053
Damevska K, Sotirovski T, Batkoska B, Djambazova M, Radeski V, Simonoska J, et al. COVID 19 associated Telogen Effluvium After Hospital Discharge: A Prospective Cohort Study. Acta Dermatovenerol Croat. 2024;32(1):33–38.
Manca E, di Toma M, Esotico M, Soldano L, Polito AN, Mongelli G, et al. Asymptomatic SARS COV2 Infection or COVID 19 vaccination effect for severe multisystem inflammatory syndrome in a 6 year old girl: case report and review of the literature. Ital J Pediatr. 2024;50(1):194. doi:10.1186/s13052-024-01234-5
Chrabieh R, Haddad I, Salameh P, Kurban M, Kechichian E, Habre M, et al. Dermatological manifestations associated with COVID 19 and COVID 19 vaccination: results from the Lebanese COVID registry. Int J Dermatol. 2023;62(10):1248–1256. doi:10.1111/ijd.16312
Özen T, Kahraman FC, Öcal S, Ovalı HF. Skin, mucosa and nail findings in hospitalized pediatric patients with Coronavirus disease 2019 (COVID 19). An Bras Dermatol. 2023;98(2):208–215. doi:10.1016/j.abd.2022.07.010
Saki N, Aslani FS, Sepaskhah M, Shafiei M, Alavizadeh S, Hosseini SA, et al. Intermittent chronic telogen effluvium with an unusual dermoscopic finding following COVID 19. Clin Case Rep. 2022;10(8):e6228. doi:10.1002/ccr3.6228
Savaş Şen Z, Polat M, Öz FN, Tanır G. Hair Loss as a Late Complication of Multisystem Inflammatory Syndrome in Children. Pediatr Infect Dis J. 2021;40(6):251–252. doi:10.1097/INF.0000000000003202
Iancu GM, Molnar E, Ungureanu L, Șenilă SC, Hașegan A, Rotaru M. SARS CoV 2 Infection – A Trigger Factor for Telogen Effluvium: Review of the Literature with a Case Based Guidance for Clinical Evaluation. Life. 2023;13(7):1576. doi:10.3390/life13071576
Olds H, Liu J, Luk K, Lim HW, Ozog D, Rambhatla PV. Telogen effluvium associated with COVID 19 infection. Dermatol Ther. 2021;34(2):e14726. doi:10.1111/dth.14726
